The patient scheduled to undergo percutaneous coronary intervention due to ischemic heart disease
Conditions
Interventions
The patient are randomized in two loading dose groups. a) clopidgrel loading dose 300mg b) clopidgrel loading dose 600mg
The patient are randomized in two maintenance dose groups. i) clopidgrel mai
Sponsors
Department of Cardiovascular Medicine, Kyoto University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patient,who are suspected ischemic heart disease due to examination or symptom, taking low dose aspirin over a week. The patient scheduled to undergo the percutaneous coronary intervention.
Exclusion criteria
Exclusion criteria: the patient of ST elevation myocardial infarction the patient of Contraindication of aspirin or clopidgrel the patient undergoing anticoagulation with coumadin the patient who underwent thrombolysis within 2 weeks the patient who underwent antiplatelet therapy besides aspirin the patient who taking corticosteroid the patient who taking proton pump inhibitor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inhibition of platelet aggregation after 24 hours since the clopidgrel loading | — |
Secondary
| Measure | Time frame |
|---|---|
| Inhibition of platelet aggregation after a week since the clopidgrel loading The clinical and adverse event at 28 days after the PCI | — |
Countries
Japan
Contacts
Public ContactJunichi Tazaki
Graduate School of Medicine, Kyoto University Department of Cardiovascular Medicine
Outcome results
None listed